Skip to main content
AAN.com
Articles
November 7, 2012

Acute EEG findings in children with febrile status epilepticus
Results of the FEBSTAT study

November 27, 2012 issue
79 (22) 2180-2186

ABSTRACT

Objective:

The FEBSTAT (Consequences of Prolonged Febrile Seizures) study is prospectively addressing the relationships among serial EEG, MRI, and clinical follow-up in a cohort of children followed from the time of presentation with febrile status epilepticus (FSE).

Methods:

We recruited 199 children with FSE within 72 hours of presentation. Children underwent a detailed history, physical examination, MRI, and EEG within 72 hours. All EEGs were read by 2 teams and then conferenced. Associations with abnormal EEG were determined using logistic regression. Interrater reliability was assessed using the κ statistic.

Results:

Of the 199 EEGs, 90 (45.2%) were abnormal with the most common abnormality being focal slowing (n = 47) or attenuation (n = 25); these were maximal over the temporal areas in almost all cases. Epileptiform abnormalities were present in 13 EEGs (6.5%). In adjusted analysis, the odds of focal slowing were significantly increased by focal FSE (odds ratio [OR] = 5.08) and hippocampal T2 signal abnormality (OR = 3.50) and significantly decreased with high peak temperature (OR = 0.18). Focal EEG attenuation was also associated with hippocampal T2 signal abnormality (OR = 3.3).

Conclusions:

Focal EEG slowing or attenuation are present in EEGs obtained within 72 hours of FSE in a substantial proportion of children and are highly associated with MRI evidence of acute hippocampal injury. These findings may be a sensitive and readily obtainable marker of acute injury associated with FSE.

Get full access to this article

View all available purchase options and get full access to this article.

Supplementary Material

File (acute_eeg_findings.pdf)
File (wnl204447-459644_coinvestigators.docx)
File (wnl204447-459644_contributors.docx)

REFERENCES

1.
Maytal J, Shinnar S, Moshe SL, Alvarez LA. Low morbidity and mortality of status epilepticus in children. Pediatrics 1989;83:323–331.
2.
Annegers JF, Hauser WA, Shirts SB, Kurland LT. Factors prognostic of unprovoked seizures after febrile convulsions. N Engl J Med 1987;316:493–498.
3.
Abou-Khalil B, Andermann E, Andermann F, Olivier A, Quesney LF. Temporal lobe epilepsy after prolonged febrile convulsions: excellent outcome after surgical treatment. Epilepsia 1993;34:878–883.
4.
Cendes F, Andermann F, Dubeau F, et al. Early childhood prolonged febrile convulsions, atrophy and sclerosis of mesial structures, and temporal lobe epilepsy: an MRI volumetric study. Neurology 1993;43:1083–1087.
5.
French JA, Williamson PD, Thadani VM, et al. Characteristics of medial temporal lobe epilepsy: I. Results of history and physical examination. Ann Neurol 1993;34:774–780.
6.
Camfield P, Camfield C, Gordon K, Dooley J. What types of epilepsy are preceded by febrile seizures? A population-based study of children. Dev Med Child Neurol 1994;36:887–892.
7.
Berg AT, Shinnar S, Levy SR, Testa FM. Childhood-onset epilepsy with and without preceding febrile seizures. Neurology 1999;53:1742–1748.
8.
Shinnar S. Febrile seizures and mesial temporal sclerosis. Epilepsy Curr 2003;3:115–118.
9.
Shinnar S. Do febrile seizures lead to temporal lobe epilepsy? Prospective and epidemiological studies. In:, Baram TZ, Shinnar S, editors. Febrile Seizures. San Diego: Academic Press; 2002:87–101.
10.
Shinnar S, Hesdorffer DC, Nordli DR, et al. Phenomenology of prolonged febrile seizures: results of the FEBSTAT study. Neurology 2008;71:170–176.
11.
Guidelines for epidemiologic studies on epilepsy. Commission on Epidemiology and Prognosis, International League Against Epilepsy. Epilepsia 1993;34:592–596.
12.
Treatment of convulsive status epilepticus. Recommendations of the Epilepsy Foundation of America's Working Group on Status Epilepticus. JAMA 1993;270:854–859.
13.
National Institutes of Health. Febrile Seizures: Consensus Development Conference Summary. Bethesda: National Institutes of Health; 1980.
14.
Shinnar S, Bello JA, Chan S, et al. MRI abnormalities following febrile status epilepticus in children: the FEBSTAT study. Neurology 2012;79:871–877.
15.
American Clinical Neurophysiology Society. Guideline 2: minimal technical standards for pediatric electroencephalography. Available at: http://www.acns.org. Accessed February 20, 2006.
16.
Fleiss JL. Statistical Methods for Rates and Proportions. New York: John Wiley & Sons; 1981.
17.
Janszky J, Woermann FG, Barsi P, Schulz R, Halasz P, Ebner A. Right hippocampal sclerosis is more common than left after febrile seizures. Neurology 2003;60:1209–1210.
18.
Dube CM, Ravizza T, Hamamura M, et al. Epileptogenesis provoked by prolonged experimental febrile seizures: mechanisms and biomarkers. J Neurosci 2010;30:7484–7494.
19.
Lennox MA. Febrile convulsions in childhood, a clinical and electroencephalographic study. Am J Dis Child 1949;78:868–882.
20.
Millichap JG, Madsen JA, Aledort LM. Studies in febrile seizures. V. Clinical and electroencephalographic study in unselected patients. Neurology 1960;10:643–653.
21.
Lerique-Koechlin A, Misès J, Teyssonière de Gramont M, Losky-Nekhorocheff I. The EEG in febrile seizures [in French]. Rev Neurol (Paris) 1958;99:11–25.
22.
Frantzen E, Lennox-Buchthal M, Nygaard A. Longitudinal EEG and clinical study of children with febrile convulsions. Electroencephalogr Clin Neurophysiol 1968;24:197–212.
23.
Doose H, Petersen CE, Volzke E, Herzberger E. Fever cramps and epilepsy. I. Etiology, clinical picture and course of the so-called infection or fever cramps [in German]. Arch Psychiatr Nervenkr 1966;208:400–412.
24.
Prichard JS, McGreal DA. Febrile convulsions. Med Clin North Am 1958;42:379–387.
25.
Mathern GW, Pretorius JK, Babb TL. Influence of the type of initial precipitating injury and at what age it occurs on course and outcome in patients with temporal lobe seizures. J Neurosurg 1995;82:220–227.
26.
Gomes WA, Shinnar S. Prospects for imaging-related biomarkers of human epileptogenesis: a critical review. Biomark Med 2011;5:599–606.
27.
Engel J. Biomarkers in epilepsy: introduction. Biomark Med 2011;5:537–544.
28.
Galanopoulou AS, Moshe SL. In search of epilepsy biomarkers in the immature brain: goals, challenges and strategies. Biomark Med 2011;5:615–628.

Information & Authors

Information

Published In

Neurology®
Volume 79Number 22November 27, 2012
Pages: 2180-2186
PubMed: 23136262

Publication History

Received: May 8, 2012
Accepted: July 9, 2012
Published online: November 7, 2012
Published in print: November 27, 2012

Permissions

Request permissions for this article.

Disclosure

D. Nordli is funded by the NIH. S. Moshé is funded by the NIH and the Heffer and Segal Family Foundations and received a consultant fee from Eisai and a speaker's fee and travel expenses from GSK. S. Shinnar is funded by the NIH, served on a DSMB for King Pharmaceuticals, has received personal compensation for serving on Scientific Advisory Boards for Questcor and Sunovion, for consulting for Eisai, Questcor, and Neuronex, and speaker honoraria from Eisai, Questcor, and UCB. D. Hesdorffer is funded by the NIH, the CDC, AUCD, Maternal and Child Health Bureau, and grants from the Epilepsy Study Consortium and Epilepsy Foundation of America. She has served on the UCB advisory board. She is a consultant to Mt. Sinai Medical Center, New York, and has a received a travel grant award from GlaxoSmithKline. Y. Sogawa has received support in the form of the Susan Spencer Young Clinical Investigator Award from the American Epilepsy Society. She was an NSADA trainee under K12 NS-48856. J. Pellock is funded by the NIH and the CDC. He has also received research support from Eisai, Marinus, Lundbeck, Pfizer, Questcor, and UCB. He has received compensation for serving on Scientific Advisory Boards for Eisai, Lundbeck, Questcor, Sepracor, and UCB. He has been a consultant for Catalyst, Eisai, GlaxoSmithKline, King, KV Pharmaceuticals, Lundbeck, Marinus, Neuropace, Pfizer, Questcor, Sepracor, Sunovion, UCB, Upsher Smith, and Valeant. All grants, research support, consultant fees, and honoraria are paid to Virginia Commonwealth University or the physician practice plan (MCV Physicians). D. Lewis is funded by the NIH. L.M. Frank is funded by the NIH and has received grant support from Schwarz-UCB, Ovation-Lundbeck, Eisai, Supernus, and AVI BioPharma. He holds or has held stock in AVI Biopharma, Oncothyreon, Neurologix, Peregrine, Positiveid, and Nanoviricides. R. Shinnar is funded by the NIH. She has received compensation for serving on advisory panels for Questcor Pharmaceuticals, Eisai, and Lundbeck and speaker honoraria from Cyberonics and Questcor. S. Sun is funded by the NIH and serves as a consultant for Nestle. Go to Neurology.org for full disclosures.

Authors

Affiliations & Disclosures

Douglas R. Nordli, Jr, MD
From Neurology (D.R.N.), Children's Memorial Hospital, Chicago, IL; Neurology and Pediatrics (S.L.M., S. Shinnar, Y.S., R.C.S.), Montefiore Med Center, Albert Einstein College of Medicine, Bronx; Epidemiology (D.C.H.), Columbia University, New York, NY; Neurology (J.M.P.), Virginia Commonwealth University, Richmond, VA; Pediatrics (Neurology) (D.V.L.), Duke University Medical Center, Durham, NC; Neurology (L.M.F.), Children's Hospital of The King's Daughters, Eastern Virginia Medial School, Norfolk; and Biostatistics and International Epilepsy Consortium (S. Sun), Virginia Commonwealth University, Richmond, VA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Epileptic Disorders, Associate Editor (2009-present)
Patents:
1.
NONE
Publishing Royalties:
1.
I have been a section editor for UpToDate for the past several years.
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
I am a co-investigator sponsored by NIH/NINDS 1-RO1-NS43209.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Solomon L. Moshé, MD
From Neurology (D.R.N.), Children's Memorial Hospital, Chicago, IL; Neurology and Pediatrics (S.L.M., S. Shinnar, Y.S., R.C.S.), Montefiore Med Center, Albert Einstein College of Medicine, Bronx; Epidemiology (D.C.H.), Columbia University, New York, NY; Neurology (J.M.P.), Virginia Commonwealth University, Richmond, VA; Pediatrics (Neurology) (D.V.L.), Duke University Medical Center, Durham, NC; Neurology (L.M.F.), Children's Hospital of The King's Daughters, Eastern Virginia Medial School, Norfolk; and Biostatistics and International Epilepsy Consortium (S. Sun), Virginia Commonwealth University, Richmond, VA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
GSK: Honorarium and travel for a talk
Editorial Boards:
1.
Neurobiology of disease: Associate editor (2007-); Editorial Board: Pediatric Neurology(2001-); Epileptic Disorders(2001-); Brain and Development(1994-); and Physiological Research (1992-).
Patents:
1.
NONE
Publishing Royalties:
1.
Models of Seizures and Epilepsy, Elsevier (2005); Epileptic Disorders, Clinical Neurophysiology of Infancy and Childhood, Butterworth-Heineman Elsevier (2006)
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
One time only: Eisai
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NINDS: NS20253: PI 1984-; NINDS: NS43209, Investigator 2002-; NINDS: NS45911, Investigator 2003-;
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Heffer Family Foundation (philanthropy); Segal Family Foundation (philanthropy)
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Shlomo Shinnar, MD, PhD
From Neurology (D.R.N.), Children's Memorial Hospital, Chicago, IL; Neurology and Pediatrics (S.L.M., S. Shinnar, Y.S., R.C.S.), Montefiore Med Center, Albert Einstein College of Medicine, Bronx; Epidemiology (D.C.H.), Columbia University, New York, NY; Neurology (J.M.P.), Virginia Commonwealth University, Richmond, VA; Pediatrics (Neurology) (D.V.L.), Duke University Medical Center, Durham, NC; Neurology (L.M.F.), Children's Hospital of The King's Daughters, Eastern Virginia Medial School, Norfolk; and Biostatistics and International Epilepsy Consortium (S. Sun), Virginia Commonwealth University, Richmond, VA.
Disclosure
Scientific Advisory Boards:
1.
King Pharmaceuticals - DSMB member; Questcor - scientific advisory board; Sunovion - scientific advisory board; Upsher-Smith - Scientific Advisory Board Spouse served on Scientific Advisory Board for Eisai
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Cyberonics Speaker honoraria; Eisai - speaker honoraria; Questcor - speaker honoraria ; Lundbeck - speaker honoraria (spouse)
Editorial Boards:
1.
Pediatric Neurology - editorial board member 1995-present
Patents:
1.
NONE
Publishing Royalties:
1.
Febrile Seizures, Baram TZ and Shinnar S Editors, Acdemic, Presss 2002
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Questcor - consultant past 2 years; Eisai - Consultant past 2 years; NeuroNEX - Consultant past year Upsher-Smith Consultant - 2012
Speakers' Bureaus:
1.
Cyberonics - Speakers bureau; Eisai - Speaker Bureau - past 2 years; Questcor - speaker bureau past 2 years; Lundbeck - Speaker bureau(spouse)
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIH/NINDS R01 NS43209 2003-2013 (PI), NIH/NINDS R01 NS045911 2003-2014 - Coinvestigator and Member of executive committee, NIH/NINDS R01 NS053998 2007-2012 Co-Investigator, NIH/NINDS 1U10NS077308 2011-2018 PD, Co-PI, NIH/NCRR 5 UL1 RR025759 2008-2012 Director regulatory support
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Dale C. Hesdorffer, PhD
From Neurology (D.R.N.), Children's Memorial Hospital, Chicago, IL; Neurology and Pediatrics (S.L.M., S. Shinnar, Y.S., R.C.S.), Montefiore Med Center, Albert Einstein College of Medicine, Bronx; Epidemiology (D.C.H.), Columbia University, New York, NY; Neurology (J.M.P.), Virginia Commonwealth University, Richmond, VA; Pediatrics (Neurology) (D.V.L.), Duke University Medical Center, Durham, NC; Neurology (L.M.F.), Children's Hospital of The King's Daughters, Eastern Virginia Medial School, Norfolk; and Biostatistics and International Epilepsy Consortium (S. Sun), Virginia Commonwealth University, Richmond, VA.
Disclosure
Scientific Advisory Boards:
1.
(1) Commercial entity
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
GSK for a platform presentation at the ECE 2010
Editorial Boards:
1.
Editorial Board, Epilepsia, 2008-2011; Editorial Board, Epilepsy Research, 2007-present; Editorial Board, Epilepsy and Behavior 2011-present; Contributing editor, Epilepsy Currents, 2009- present
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Mount Sinai Medical Center, Injury prevention grant
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
1. CDC, DP002209, PI, 2009-2014; 2. AUCD, RT01, Co-I (PI of Columbia subcontract), 2008-2011; 3. NINDS, NS31146, Co-I (PI of Columbia subcontract), 2007-2014; 4. NINDS, NS043209, Co-I (PI of Columbia subcontract), 2003-2013; 5. CDC, MM1002, Co-I, 2006-2010; 6. Maternal and Child Health Bureau, MC00007, Co-I, 2005-2011; 7. NICHD, HD042823, Co-I, 2002-2013; 8. NINDS, 5U01NS04911, Co-I (PI of Columbia subcontract), 2011-2012; 9. NINDS, NS078419, Co-I, 2012-2015
Research Support, Academic Entities:
1.
Epilepsy Study Consortium, Inc. PI of subcontract to Columbia University, 1/1/2010-12/31/2011
Research Support, Foundations and Societies:
1.
Epilepsy Foundation of America 2010-2012
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Yoshimi Sogawa, MD
From Neurology (D.R.N.), Children's Memorial Hospital, Chicago, IL; Neurology and Pediatrics (S.L.M., S. Shinnar, Y.S., R.C.S.), Montefiore Med Center, Albert Einstein College of Medicine, Bronx; Epidemiology (D.C.H.), Columbia University, New York, NY; Neurology (J.M.P.), Virginia Commonwealth University, Richmond, VA; Pediatrics (Neurology) (D.V.L.), Duke University Medical Center, Durham, NC; Neurology (L.M.F.), Children's Hospital of The King's Daughters, Eastern Virginia Medial School, Norfolk; and Biostatistics and International Epilepsy Consortium (S. Sun), Virginia Commonwealth University, Richmond, VA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
John M. Pellock, MD
From Neurology (D.R.N.), Children's Memorial Hospital, Chicago, IL; Neurology and Pediatrics (S.L.M., S. Shinnar, Y.S., R.C.S.), Montefiore Med Center, Albert Einstein College of Medicine, Bronx; Epidemiology (D.C.H.), Columbia University, New York, NY; Neurology (J.M.P.), Virginia Commonwealth University, Richmond, VA; Pediatrics (Neurology) (D.V.L.), Duke University Medical Center, Durham, NC; Neurology (L.M.F.), Children's Hospital of The King's Daughters, Eastern Virginia Medial School, Norfolk; and Biostatistics and International Epilepsy Consortium (S. Sun), Virginia Commonwealth University, Richmond, VA.
Disclosure
Scientific Advisory Boards:
1.
NIH; Lundbeck, vigabatrin DSMB; Eisai; GlaxoSmithKline; King Pharmaceuticals; KV Pharmaceuticals; Marinus Pharmaceuticals; Neuropace - DSMB; Pfizer; Questcor; Sepracor; Sunovian; UCB Pharmaceuticals; Upsher-Smith; Valeant
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Editorial Board - Journal of Child Neurology, 1997-, present; Editorial Board- Journal of Epileptic Disorders, 2000- present; Editorial Board, Pediatric Neurology, 2000-present; Editorial Board, Current Drug Safety, 2006-present
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NIH; Catalyst; Lundbeck, vigabatrin DSMB; Eisai; GlaxoSmithKline; King Pharmaceuticals; KV Pharmaceuticals; Marinus Pharmaceuticals; Neuropace - DSMB; Pfizer; Questcor; Sepracor; Sunovian; UCB Pharmaceuticals; Upsher-Smith; Valeant
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Eisai; Marinus Pharmaceuticals; Lundbeck; Pfizer; Questcor; UCB Pharmaceuticals; Upsher-Smith
Research Support, Government Entities:
1.
NIH; CDC/HRSA
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
Member of Virginia Birth Related Injury Review Panel (through VCU)
Darrell V. Lewis, MD
From Neurology (D.R.N.), Children's Memorial Hospital, Chicago, IL; Neurology and Pediatrics (S.L.M., S. Shinnar, Y.S., R.C.S.), Montefiore Med Center, Albert Einstein College of Medicine, Bronx; Epidemiology (D.C.H.), Columbia University, New York, NY; Neurology (J.M.P.), Virginia Commonwealth University, Richmond, VA; Pediatrics (Neurology) (D.V.L.), Duke University Medical Center, Durham, NC; Neurology (L.M.F.), Children's Hospital of The King's Daughters, Eastern Virginia Medial School, Norfolk; and Biostatistics and International Epilepsy Consortium (S. Sun), Virginia Commonwealth University, Richmond, VA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NINDS 5R01-NS043209-08, local PI, 9
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
L. Matthew Frank, MD
From Neurology (D.R.N.), Children's Memorial Hospital, Chicago, IL; Neurology and Pediatrics (S.L.M., S. Shinnar, Y.S., R.C.S.), Montefiore Med Center, Albert Einstein College of Medicine, Bronx; Epidemiology (D.C.H.), Columbia University, New York, NY; Neurology (J.M.P.), Virginia Commonwealth University, Richmond, VA; Pediatrics (Neurology) (D.V.L.), Duke University Medical Center, Durham, NC; Neurology (L.M.F.), Children's Hospital of The King's Daughters, Eastern Virginia Medial School, Norfolk; and Biostatistics and International Epilepsy Consortium (S. Sun), Virginia Commonwealth University, Richmond, VA.
Disclosure
Scientific Advisory Boards:
1.
Commonwealth (Virginia) Health Research Board, non-profit
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
Children's Specialty Group, physician.
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
Board of Directors, Chesapeake Bay Academy, a school for special needs children.
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Schwarz-UCB, Ovation-Lundbeck, Eisai, Supernus, AVI Biopharma, Astra Zeneca, Bristol-Meyers Squibb, Otsuka.
Research Support, Government Entities:
1.
NIH Grants NS043209 and NS045911, Investigator.
Research Support, Academic Entities:
1.
Eastern Virginia Medical School, Professor.
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
AVI Biopharma, Oncothyreon, NeuroLogix, Peregrine, PositivId, Nanoviricides.
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
AVI Biopharma, 2012.
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
Medical-legal consulting
Ruth C. Shinnar, RN, MSN
From Neurology (D.R.N.), Children's Memorial Hospital, Chicago, IL; Neurology and Pediatrics (S.L.M., S. Shinnar, Y.S., R.C.S.), Montefiore Med Center, Albert Einstein College of Medicine, Bronx; Epidemiology (D.C.H.), Columbia University, New York, NY; Neurology (J.M.P.), Virginia Commonwealth University, Richmond, VA; Pediatrics (Neurology) (D.V.L.), Duke University Medical Center, Durham, NC; Neurology (L.M.F.), Children's Hospital of The King's Daughters, Eastern Virginia Medial School, Norfolk; and Biostatistics and International Epilepsy Consortium (S. Sun), Virginia Commonwealth University, Richmond, VA.
Disclosure
Scientific Advisory Boards:
1.
Eisai and Questcor.
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Eisai, Lundbeck, Questcor and Cyberonics. US Department of Justice.
Speakers' Bureaus:
1.
Questcor and Cyberonics.
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIH/NINDS - 1.FEBTAT Study, Coordinator, 2003 - present 2.CAE study, Coordinator, QOL core member, 2003 - present
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Shumei Sun, PhD
From Neurology (D.R.N.), Children's Memorial Hospital, Chicago, IL; Neurology and Pediatrics (S.L.M., S. Shinnar, Y.S., R.C.S.), Montefiore Med Center, Albert Einstein College of Medicine, Bronx; Epidemiology (D.C.H.), Columbia University, New York, NY; Neurology (J.M.P.), Virginia Commonwealth University, Richmond, VA; Pediatrics (Neurology) (D.V.L.), Duke University Medical Center, Durham, NC; Neurology (L.M.F.), Children's Hospital of The King's Daughters, Eastern Virginia Medial School, Norfolk; and Biostatistics and International Epilepsy Consortium (S. Sun), Virginia Commonwealth University, Richmond, VA.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Consultant for Nestle
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
1R01HD060913, NIH, 03/01/2009 -02/28/2012, PI, 7R01DK071485, NIH, 05/15/2008 - 07/31/2012, PI, 1U01HL101064,NIH,09/15/2009 - 06/30/2014, PI, 1UL1RR031990, NIH,07/01/2010 - 03/31/2015, Co-, IR01HD038356, NIH, 09/28/2007 - 08/31/2013, PI, R01HD038356-07S, NIH, 08/01/2010 - 07/31/2012, PI 2R01HL040619-16, NIH, 08/23/2010 - 06/30/2012, Co-I, R01NS043209, NIH, 05/01/2010 - 04/30/2014, subcontract PI
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
For the FEBSTAT Study Team
From Neurology (D.R.N.), Children's Memorial Hospital, Chicago, IL; Neurology and Pediatrics (S.L.M., S. Shinnar, Y.S., R.C.S.), Montefiore Med Center, Albert Einstein College of Medicine, Bronx; Epidemiology (D.C.H.), Columbia University, New York, NY; Neurology (J.M.P.), Virginia Commonwealth University, Richmond, VA; Pediatrics (Neurology) (D.V.L.), Duke University Medical Center, Durham, NC; Neurology (L.M.F.), Children's Hospital of The King's Daughters, Eastern Virginia Medial School, Norfolk; and Biostatistics and International Epilepsy Consortium (S. Sun), Virginia Commonwealth University, Richmond, VA.

Notes

Correspondence & reprint requests to Dr. Nordli: [email protected]
Study funding: Supported by NIH/National Institute of Neurological Disorders and Stroke grant NS43209 (principal investigator, S. Shinnar, MD, PhD).
Presented in part at the American Epilepsy Society Annual Meeting, December 2005.
FEBSTAT coinvestigators are listed on the Neurology® Web site at www.neurology.org.
Go to Neurology.org for full disclosures. Disclosures deemed relevant by the authors, if any, are provided at the end of this article.

Author Contributions

All authors participated in the design and execution of the overall FEBSTAT project. Drs. Nordli, Moshé, and Shinnar designed the specific EEG project reported in this article. Drs. Nordli, Moshé, Sogawa, and Shinnar participated in the interpretation of the EEG tracings and their significance. All authors participated in the execution of the work reported in this article. Drs. Hesdorffer, Sun, and Shinnar performed the data analysis and statistical analysis. All authors participated in writing and editing the manuscript.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Strategies to innovate emergency care of status epilepticus, Neurotherapeutics, 22, 1, (e00514), (2025).https://doi.org/10.1016/j.neurot.2024.e00514
    Crossref
  2. Status Epilepticus in Children, Status Epilepticus - Recent Advances in Epidemiology, Electroencephalography, Etiology, Diagnosis, and Treatment in Adults and Children, (2024).https://doi.org/10.5772/intechopen.99773
    Crossref
  3. Complex Febrile Seizures: Usual and the Unusual, Indian Journal of Pediatrics, 92, 1, (44-51), (2024).https://doi.org/10.1007/s12098-024-05301-z
    Crossref
  4. Exploring the Age-Old Question: What Is the Predictive Value of EEG for Future Epilepsy in Children With Complex Febrile Seizures?, Journal of Child Neurology, 38, 5, (290-297), (2023).https://doi.org/10.1177/08830738231171799
    Crossref
  5. Efficacy of cEEG and hepatic function to diagnose early acute encephalopathy , Pediatrics International, 65, 1, (2023).https://doi.org/10.1111/ped.15494
    Crossref
  6. Why ketamine, Epilepsy & Behavior, 141, (109066), (2023).https://doi.org/10.1016/j.yebeh.2022.109066
    Crossref
  7. Predicting seizure recurrence after an initial seizure-like episode from routine clinical notes using large language models: a retrospective cohort study, The Lancet Digital Health, 5, 12, (e882-e894), (2023).https://doi.org/10.1016/S2589-7500(23)00179-6
    Crossref
  8. EEG for assessing the impact of febrile status epilepticus and predicting outcomes, Febrile Seizures, (303-311), (2023).https://doi.org/10.1016/B978-0-323-89932-1.00014-7
    Crossref
  9. Evaluation and practical management: Approach to simple and complex febrile seizures, Febrile Seizures, (315-328), (2023).https://doi.org/10.1016/B978-0-323-89932-1.00006-8
    Crossref
  10. Febrile status epilepticus and its consequences: Insights from the “Consequences of Febrile Status Epilepticus in Childhood” (FEBSTAT) study, Febrile Seizures, (115-120), (2023).https://doi.org/10.1016/B978-0-323-89932-1.00003-2
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Figures

Tables

Media

Share

Share

Share article link

Share